PTLA: Full Results ANNEXA-4 @ Intn'l Stroke Conference
Jan 30, 2019 14:04:54 GMT
miamianne67, tomsylver, and 1 more like this
Post by icemandios on Jan 30, 2019 14:04:54 GMT
Portola Pharmaceuticals to Present Full Results from the ANNEXA-4 Study of Andexxa During a Late-Breaking Oral Presentation at the International Stroke Conference 2019
Results to be presented on Thursday, February 7, 2019 at 11:36 a.m. HST/4:36 p.m. EST
Andexxa received both U.S. Orphan Drug and U.S. Food and Drug Administration (FDA) Breakthrough Therapy designations, and was approved on May 3, 2018 under the FDA's Accelerated Approval pathway. It is the first and only antidote indicated for patients treated with rivaroxaban or apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.
Session Title: Thursday Main Event
Session Number: ME II
Presenter: Truman J. Milling Jr., M.D., FACEP, Seton Dell Medical School Stroke Institution
Presentation Date and Time: Thursday, February 7, 2019 at 11:36 a.m. HST
Location: Hawaii Convention Center, Hall III
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s two FDA-approved medicines are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding, and Bevyxxa® (betrixaban), the first and only oral, once-daily Factor Xa inhibitor for the prevention of VTE in adult patients hospitalized for an acute medical illness. The company also is advancing cerdulatinib, a Syk/JAK inhibitor for the treatment of hematologic cancers.
